Efficacy and Safety of Icotrokinra for Plaque Psoriasis: A Systematic Review and Meta-analysis

Clicks: 3
ID: 317614
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #56 of 172 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 172 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background In biologic therapies targeting interleukin-23 (IL-23) for plaque psoriasis, parenteral administration can limit treatment adherence and quality of life. Icotrokinra is a first-in-class oral peptide that selectively antagonizes the IL-23 receptor and has shown promising efficacy in phase 2 and phase 3 trials. However, a comprehensive synthesis of efficacy and safety across these trials is currently lacking. Objectives To evaluate the efficacy and safety of Icotrokinra in adolescents (>12 years) and adults (>18) with moderate-to-severe plaque psoriasis. Methods PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials were searched on December 8th, 2025, with reference lists hand-searched for addition studies. Randomized controlled trials enrolling the target population which compared icotrokinra with placebo and reported efficacy or safety outcomes were included. Results Five randomized controlled trials (one phase 2 and four phase 3), comprising 4 reports, met inclusion criteria. Icotrokinra significantly increased the likelihood of achieving IGA 0/1 at week 16 compared with placebo (RR, 7.27; 95% CI, 5.80–9.11), with no heterogeneity (I2=0%). High-level skin clearance, represented by Psoriasis Area and Severity Index 90 was also significantly improved (RR, 13.82; 95% CI, 7.21-26.51). Rates of treatment-emergent and serious adverse events were comparable between icotrokinra and placebo, with no new safety signals identified over the 16-week trial period. Conclusion Icotrokinra has shown short-term efficacy and a favorable safety profile in patients with moderate-to-severe plaque psoriasis. Combining biologic-level efficacy with ease of administration, icotrokinra may represent an important advance in psoriasis therapy.
Reference Key
openalex_W7165013691 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sunaina Advani, Advait Raja, Tatiana Giraldo, Sümeyye Aktaş, Ayomide Lawal, Alfonso Gotor‐Rivera
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag255
URL
https://doi.org/10.1093/ced/llag255
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.